Literature DB >> 27622046

Chemotherapy and immunotherapy: A close interplay to fight cancer?

Aurélie Hanoteau1, Muriel Moser1.   

Abstract

In theory, the immunotherapy of cancer should induce the selective destruction of cancer cells and a long-term specific protection, based on the specificity and memory of immunity. This contrasts with the collateral damages of conventional therapies and their toxic effects on host tissues. However, recent data suggest that chemotherapy may potentiate ongoing immune responses, through homeostatic mechanisms. Massive tumor death, empty "immune" niches and selected cytokines may act as a danger signal, alerting the immune system and amplifying pre-existing antitumor reactivity.

Entities:  

Keywords:  Chemotherapy; IL-7/IL-15; drug efflux; homeostasis; immunotherapy; lymphopenia; memory T cells

Year:  2016        PMID： 27622046      PMCID： PMC5006929          DOI： 10.1080/2162402X.2016.1190061

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  50 in total

1.  Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments.

Authors:  Qing Ge; Hui Hu; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

2.  Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.

Authors:  Silvia A Fuertes Marraco; Charlotte Soneson; Laurène Cagnon; Philippe O Gannon; Mathilde Allard; Samia Abed Maillard; Nicole Montandon; Nathalie Rufer; Sophie Waldvogel; Mauro Delorenzi; Daniel E Speiser
Journal:  Sci Transl Med       Date:  2015-04-08       Impact factor: 17.956

3.  Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.

Authors:  W Nicholas Haining; Donna S Neuberg; Heather L Keczkemethy; John W Evans; Stephen Rivoli; Rebecca Gelman; Howard M Rosenblatt; William T Shearer; Javier Guenaga; Daniel C Douek; Lewis B Silverman; Stephen E Sallan; Eva C Guinan; Lee M Nadler
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

4.  T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Authors:  Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

6.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

Review 7.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 8.  Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy.

Authors:  Jianbao Gao; Lintao Zhao; Yisong Y Wan; Bo Zhu
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

9.  Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells.

Authors:  Joyce T Tan; Bettina Ernst; William C Kieper; Eric LeRoy; Jonathan Sprent; Charles D Surh
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Authors:  Claude Sportès; Frances T Hakim; Sarfraz A Memon; Hua Zhang; Kevin S Chua; Margaret R Brown; Thomas A Fleisher; Michael C Krumlauf; Rebecca R Babb; Catherine K Chow; Terry J Fry; Julie Engels; Renaud Buffet; Michel Morre; Robert J Amato; David J Venzon; Robert Korngold; Andrew Pecora; Ronald E Gress; Crystal L Mackall
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307
View more
  11 in total

Review 1.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

Review 2.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 3.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

4.  Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Authors:  Aurélie Hanoteau; Coralie Henin; David Svec; Charlotte Bisilliat Donnet; Sébastien Denanglaire; Didier Colau; Pedro Romero; Oberdan Leo; Benoit Van den Eynde; Muriel Moser
Journal:  Oncoimmunology       Date:  2017-05-11       Impact factor: 8.110

Review 5.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 6.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

Review 7.  Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.

Authors:  Ondrej Uher; Veronika Caisova; Per Hansen; Jan Kopecky; Jindrich Chmelar; Zhengping Zhuang; Jan Zenka; Karel Pacak
Journal:  Semin Oncol       Date:  2019-11-06       Impact factor: 4.929

Review 8.  Current status and future directions of cancer immunotherapy.

Authors:  Hongming Zhang; Jibei Chen
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

Review 9.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

Review 10.  Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications.

Authors:  Jitka Fucikova; Lenka Palova-Jelinkova; Jirina Bartunkova; Radek Spisek
Journal:  Front Immunol       Date:  2019-10-29       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.